Your SlideShare is downloading. ×
0
Path Dependence
Path Dependence
Path Dependence
Path Dependence
Path Dependence
Path Dependence
Path Dependence
Path Dependence
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Path Dependence

305

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
305
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  1. Path DependencePath Dependence Phil CookePhil Cooke Centre for Advanced Studies &Centre for Advanced Studies & CESAGenCESAGen Cardiff UniversityCardiff University
  2. Basel, Path Dependence, Pharma,Basel, Path Dependence, Pharma, GlobalisationGlobalisation • Long TimelinesLong Timelines • Competitive Strategies of EmulationCompetitive Strategies of Emulation • Public Research InfrastructurePublic Research Infrastructure • Basel-Freiburg-Strasburg ‘BioValley’ agro-Basel-Freiburg-Strasburg ‘BioValley’ agro- food & pharmaceutical biotechnologyfood & pharmaceutical biotechnology • Basel has 52 biotech spinouts (26% SwissBasel has 52 biotech spinouts (26% Swiss total)total) • Global Biotech Cluster PenetrationGlobal Biotech Cluster Penetration
  3. Basel Pharma Timelines (* Nobels)Basel Pharma Timelines (* Nobels)
  4. Basel Research CapabilitiesBasel Research Capabilities
  5. Novartis in San DiegoNovartis in San Diego
  6. Roche in San Francisco & SanRoche in San Francisco & San DiegoDiego
  7. Novartis in Cambridge & BostonNovartis in Cambridge & Boston
  8. ConclusionsConclusions • Swiss pharma the most aggressiveSwiss pharma the most aggressive collaborator/acquirer in US biotechcollaborator/acquirer in US biotech • Global cluster-based division of capabilitiesGlobal cluster-based division of capabilities • Basel for cardiovascular & oncologyBasel for cardiovascular & oncology • San Diego for immunology (HIV etc.)San Diego for immunology (HIV etc.) • San Francisco for gene therapies/technologiesSan Francisco for gene therapies/technologies • Cambridge/Boston for post-genomics &Cambridge/Boston for post-genomics & transgenicstransgenics • Syngenta in San Diego and RTP, N. CarolinaSyngenta in San Diego and RTP, N. Carolina • Strategic accessing ofStrategic accessing of Regional KnowledgeRegional Knowledge CapabilitiesCapabilities • Path Dependence Strategically EvolvedPath Dependence Strategically Evolved

×